Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions – from cell line development to final aseptic fill/finish – as well as comprehensive laboratory testing services at every stage of biopharmaceutical products.
Facilities are all CGMP compliant house bioreactors ranging from small to large scale, accommodating diverse client needs.
Samsung is setting new standards in the CDMO industry with the world’s largest biomanufacturing capacity at 845 kL expanding its capabilities through Bio Campus II, scheduled for completion in 2032.
Driven by continuous innovation and a commitment to operational excellence, Samsung works alongside its clients to deliver the speed, flexibility and trust needed to advance the future of biomanufacturing.
As a sustainable CDMO partner of choice, Samsung is dedicated to on-time, in-full delivery – powered by flexible manufacturing solutions, operational excellence and proven expertise.
